Frontline · Health Tech · 2026-05-22

Whoop's blood pressure feature stalls in FDA review, threatening clinical pivot

The wearables company remains in regulatory limbo over its contested BP monitoring feature, weeks after launching clinician video visits and EHR integration—raising questions about its wellness-to-clinical pathway.

Founded

2012

14 years

Status

Private

Total raised

$976.4M

Headcount

501-1k

The story

Whoop remains in active discussions with the FDA^[1] over its blood pressure monitoring feature, which the agency flagged in a warning letter as requiring premarket review under medical-device regulations. The feature, introduced earlier this year, uses photoplethysmography—optical sensors that measure blood volume changes—to estimate systolic and diastolic pressure without a traditional cuff. The FDA's position: any device making claims about diagnosing or managing hypertension crosses the wellness threshold into medical territory, triggering Class II device classification and a 510(k) clearance pathway. Whoop has not pulled the feature, but it's effectively frozen pending resolution. The timing is sharp: nine days before this story broke, Whoop launched on-demand clinician video visits^[2] and EHR integration via HealthEx, positioning the band as a clinical data source rather than pure fitness telemetry. The regulatory stall matters because it exposes the fragility of the wellness-to-clinical transition for wearables at scale. Whoop has framed blood pressure monitoring as a continuous, passive layer—something a traditional cuff can't deliver—and a key unlock for its new provider-facing model. Clinicians don't prescribe wearables for fun; they need FDA-cleared endpoints. Without clearance, Whoop's longitudinal BP data becomes observational color rather than actionable clinical signal, and the EHR integration loses its core value prop. The dispute also surfaces a broader tension: optical BP measurement remains contested in the literature, with accuracy questions around skin tone, wrist anatomy, and motion artifacts. The FDA is signaling it will not greenlight unproven modalities under the guise of wellness innovation, even for a company with nearly a billion in funding and a premium consumer brand. The real shift here is strategic, not just regulatory. Whoop spent a decade building a moat in the high-performance wellness segment—screenless design, subscription retention, strain-recovery methodology. That moat doesn't port cleanly into clinical workflows. Abbott's FreeStyle Libre and Omada Health own the chronic-care integration playbook because they invested in regulatory paths early, designed for payer reimbursement, and built clinical evidence bases. Whoop is trying to retrofit a consumer product into a medical device, and the FDA is forcing the question: is this a pivot or opportunistic feature creep? If the company can't clear the BP feature—or if clearance takes 18+ months—the clinical wedge dulls, and Whoop reverts to being a premium fitness tracker competing on brand, not infrastructure.

The rest of this story is for subscribers.

Including Our Take, the Tailwinds & headwinds framing, Connections across the FOBI roster, and What should you do.

Founding

50% off

/month

94 of 100 spots left

Full

$10

/month

Available once all 100 Founding Member spots are claimed.

Get full access

Already subscribed? Sign in →

In plain English

Whoop makes a subscription wristband that tracks recovery, sleep, and strain—mostly for athletes and fitness enthusiasts. The company added a blood pressure feature, but the FDA says it needs formal medical-device approval before it can be marketed. Whoop is now stuck in talks with regulators, just as it tries to expand into clinical care with doctor video visits. If the FDA blocks the feature, Whoop's bet on becoming a healthcare tool—not just a fitness tracker—gets harder.

Our Take

The real story isn't whether Whoop gets its BP feature cleared—it's that the FDA is drawing a bright line under the wellness-to-medical transition and forcing every wearable to choose: stay in the consumer lane and monetize retention, or commit capital and years to clearance pathways and clinical evidence. Whoop raised nearly a billion dollars as a premium fitness brand; retrofitting that into a medical device is expensive, slow, and uncertain. The companies that will own the clinical wearable category are the ones that designed for it from day one—cleared endpoints, payer pilots, reimbursement codes. The asymmetry isn't in betting on which consumer brand pivots successfully; it's in owning the infrastructure layer that makes the pivot possible—or obsolete.

Takeaways

01Whoop's FDA stall is a template: every wearable adding diagnostic claims will hit this regulatory wall; brand and retention don't substitute for clearance
02The clinical pivot loses its thesis if the BP feature can't clear—EHR integration without FDA-validated endpoints is observational color, not reimbursable signal
03The moat in health-tech wearables is shifting from consumer brand to regulatory infrastructure—cleared devices, payer contracts, clinical evidence bases
04Optical BP measurement remains scientifically contested; the FDA is signaling it won't greenlight unproven modalities under wellness framing

Tailwinds & headwinds

Tailwinds

Chronic-care platforms with FDA-cleared endpoints and payer contracts (Omada, Abbott) see tailwinds as the wellness-to-clinical gap widens
Regulatory-advisory and clinical-validation infrastructure providers gain pricing power as more wearables hit the device-classification wall
EHR middleware (HealthEx, Human API) captures margin if they can curate signal and liability-manage uncleared data streams

Headwinds

Consumer wearable brands without regulatory roadmaps face 18+ month stalls or forced feature rollbacks, compressing valuation multiples
Optical BP measurement's contested accuracy creates overhang for any PPG-based cardiovascular claims, limiting reimbursement pathways
Clinical partnerships (video visits, EHR feeds) lose strategic weight if the underlying sensor data remains non-diagnostic

What should you do

The asymmetric bet here is on the infrastructure layer beneath wearables—the regulatory-advisory firms, the clinical-validation platforms, the EHR middleware—not on individual consumer brands trying to self-certify their way into healthcare. Whoop's stall is a template: every Apple Watch clone, every smart ring, every continuous-monitoring startup will hit this same wall when they add a diagnostic claim. The winners will be companies that either (a) raised capital explicitly to fund multi-year FDA pathways and payer pilots, or (b) stay disciplined in the wellness lane and monetize via retention, not reimbursement. If you're long health-tech, the play is chronic-care platforms with incumbent distribution—Omada, Abbott—not consumer wearables pivoting into clinic…

Strategic-positioning commentary · not investment advice

Regulatory landscape

The FDA's enforcement posture on wearable diagnostics has hardened post-2024. The agency is requiring 510(k) submissions for any cardiovascular claim that could influence clinical decision-making—hypertension diagnosis, arrhythmia detection, ischemia alerts. Optical BP measurement is particularly scrutinized because accuracy studies show variability across skin tones, wrist sizes, and movement conditions. The bar for clearance is rising: the FDA now expects head-to-head validation against gold-standard sphygmomanometers in diverse populations, not just white-paper algorithms. For a company like Whoop, that means funding multi-site clinical trials, hiring regulatory affairs teams, and accepting an 18+ month timeline—all while the consumer product roadmap stalls. The alternative is to pull the feature and abandon the clinical thesis, but that unwinds the strategic narrative that justified the last funding round.

How they make money

Whoop's subscription model—$30/month for the band, analytics, and coaching—has been its retention moat. The clinical pivot was supposed to unlock a second revenue stream: employer wellness contracts, health-plan integrations, and eventually, remote patient monitoring reimbursement codes (RPM, CPT 99453–99457). But RPM reimbursement requires FDA-cleared devices. Without clearance, Whoop can sell data access to clinicians, but it can't bill payers directly. The margin profile splits: consumer subscriptions remain high-margin SaaS; clinical partnerships become low-margin B2B2C distribution plays with long sales cycles and compliance overhead. If the BP feature can't clear, the clinical model reverts to a marketing channel for consumer acquisition, not a standalone P&L. That's not necessarily fatal—Hims & Hers monetizes telehealth as a DTC funnel, not payer contracts—but it's a different business than the one Whoop has been pitching to growth investors.

Trajectory

Forward signals

FDA response timeline: whether Whoop receives a formal deficiency letter requiring 510(k) submission or negotiates a downgraded wellness-only claim by Q3 2026
Clinical trial initiation: if Whoop funds a head-to-head BP accuracy study against sphygmomanometer gold standard, signaling commitment to clearance pathway (6–9 month study + 3–6 month submission review)
EHR integration traction metrics: HealthEx partnership adoption by provider groups—if clinicians aren't ordering Whoop data without diagnostic claims, the clinical model thesis weakens
Competitive filings: whether Apple, Samsung, or Fitbit (Google) file 510(k)s for BP monitoring in same window, indicating industry-wide bet on regulatory path vs. wellness retreat

Report Notes

1.
CatalystSTAT News
statnews.com · 2026-05-21
2.
Whoop press release (HealthEx partnership)
whoop.com · 2026-05-12

Cast

Whoop
Abbott Laboratories (FreeStyle Libre) — Cleared chronic-care incumbent
Omada Health — Clinical-validation benchmark
Hims & Hers Health — DTC health pivot parallel

Glossary

Photoplethysmography (PPG): An optical technique that uses light sensors to measure blood volume changes in the microvascular bed of tissue. Wearables use PPG for heart rate, SpO2, and—controversially—blood pressure estimation, though accuracy for BP remains contested in peer-reviewed literature.
510(k) clearance: FDA premarket submission pathway for Class II medical devices. Requires demonstrating substantial equivalence to a legally marketed predicate device. Typical timeline: 3–12 months, but can extend if the agency requests clinical data or raises novel questions of safety and effect…
Wellness vs. medical device threshold: The regulatory line the FDA draws between general wellness products (which make only lifestyle or low-risk claims) and medical devices (which diagnose, treat, cure, mitigate, or prevent disease). Claims about hypertension or cardiovascular risk management trigger device classifi…
EHR integration: The technical and workflow process of feeding wearable or remote monitoring data into a provider's electronic health record system. Requires middleware (like HealthEx), HL7/FHIR standards, and—critically—clinical validation that the data is actionable, not just noise.